drugset
drugset / Trial / NCT05885776

Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research

NCT05885776 ↗

Phase 2 Unknown 48 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

Research topic Preoperative efficacy and safety of pyrrolitinib combined with trastuzumab and AI in the treatment of HR+/HER2+breast cancer Overall: A single arm multicenter phase II exploratory study。Subjects HR+/HER2+breast cancer patients in stage Ⅱ\~Ⅲ A。

Timeline

Start
2022-09-13
Primary completion
2024-03-30
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Anatriazole Unknown 1 mg Oral
Subject KBP-5209 Unknown 400 mg Oral
Subject Letrozole Other / unclassified 2.5 mg Oral
Subject Trastuzumab Monoclonal antibody 6 mg/kg Intravenous

Indications

breast cancer